Research programme: anti-properdin monoclonal antibodies - Abgenix/Gliatech

Drug Profile

Research programme: anti-properdin monoclonal antibodies - Abgenix/Gliatech

Alternative Names: Anti-properdin monoclonal antibodies research programme - Abgenix/Gliatech

Latest Information Update: 06 Oct 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gliatech (CEASED)
  • Class Monoclonal antibodies
  • Mechanism of Action Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders; Inflammation

Most Recent Events

  • 31 Mar 2003 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 31 Mar 2003 Discontinued - Preclinical for Inflammation in USA (unspecified route)
  • 02 Jul 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top